Kuros Biosciences Ltd. Logo

Kuros Biosciences Ltd.

Biologic tech for predictable spinal fusions, featuring the MagnetOs bone graft.

KURN | SW

Overview

Corporate Details

ISIN(s):
CH0325814116
LEI:
5299006U5POB2AVTT709
Country:
Switzerland
Address:
Wagisstraße 25, 8952 Schlieren
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kuros Biosciences is a medical technology company that discovers, develops, and delivers innovative biologic technologies for tissue repair and bone regeneration. The company's primary focus is on improving outcomes in spinal fusion surgery to address high rates of failed fusions. Its main product is MagnetOs, a bone graft featuring proprietary NeedleGrip™ surface technology, which is designed to grow bone even in soft tissues for more predictable fusions. Kuros Biosciences supports its products through 'Project Fusion,' a global research program that combines scientific, pre-clinical, and clinical studies. The company operates globally with a commercial and research footprint across three continents and more than 20 markets.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-16 02:00
Earnings Release
Kuros Biosciences increases the annual guidance for 2025, The company reports 7…
English 12.7 KB
2025-09-18 02:00
Legal Proceedings Report
Kuros statement on media inquiry concerning former Board member
English 7.6 KB
2025-09-04 02:00
Board/Management Information
Kuros Biosciences announces changes in the Board of Directors
English 7.4 KB
2025-08-14 02:00
Earnings Release
Kuros Biosciences Reports First Half of 2025 Results
English 22.7 KB
2025-03-11 01:00
Earnings Release
Kuros Biosciences grows sales to CHF 75.6 million for 2024
English 19.2 KB
2025-01-08 07:00
Legal Proceedings Report
Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the…
English 13.7 KB
2025-01-07 07:00
Regulatory Filings
Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the…
English 13.7 KB
2025-01-07 01:00
M&A Activity
Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the…
English 11.8 KB
2024-11-19 07:00
Board/Management Information
Kuros Biosciences Expands into Extremities Markets
English 18.5 KB
2024-11-19 01:00
Board/Management Information
Kuros Biosciences Expands into Extremities Markets
English 16.1 KB
2024-10-10 02:00
Earnings Release
Kuros reports 149% increase in direct MagnetOs sales and exceeds cash flow brea…
English 16.3 KB
2024-08-08 07:00
Earnings Release
Kuros Biosciences Reports First Half of 2024 Results
English 37.6 KB
2024-08-08 02:00
Earnings Release
Kuros Biosciences Reports First Half of 2024 Results
English 33.0 KB
2024-06-25 07:00
Regulatory Filings
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 …
English 17.2 KB
2024-06-25 02:00
Regulatory Filings
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 …
English 14.9 KB

Automate Your Workflow. Get a real-time feed of all Kuros Biosciences Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kuros Biosciences Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kuros Biosciences Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-23 N/A Executive member Sell None 1,264,800.00 CHF
2025-04-17 N/A Executive member Sell None 13,344.49 CHF
2025-03-18 N/A Non-Executive member Buy None 38,200.00 CHF
2024-12-11 N/A Executive member Sell None 4,702,500.00 CHF
2024-11-15 N/A Non-Executive member Buy None 925,210.00 CHF
2024-11-14 N/A Non-Executive member Sell None 592,000.00 CHF
2024-11-12 N/A Executive member Sell None 13,890.86 CHF
2024-09-25 N/A Executive member Sell None 8,226,000.00 CHF
2024-09-25 N/A Non-Executive member Sell None 3,656,000.00 CHF
2024-09-24 N/A Non-Executive member Buy None 223,720.00 CHF

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Developing targeted AAV genetic medicines for large market eye, lung, and heart diseases.
United States of America
FDMT
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Develops medical devices, diagnostics, nutritionals, and pharmaceuticals for global health.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
AbCellera Biologics Inc. Logo
An AI-powered platform that discovers and develops antibody therapeutics for pharma partners.
United States of America
ABCL
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea
174900

Talk to a Data Expert

Have a question? We'll get back to you promptly.